Pharmaceutical Executive-06-01-2018

Azar and Gottlieb out front in revising rebates, restructuring Medicare, and promoting competition.

Pharm Exec speaks with Joe Wiley, CEO of Amryt Pharma, who is steering a road-less-traveled path for a small pharma-building a sustainable, commercial infrastructure first, with the hopes of accelerating new rare disease drugs to the market.

Weighing the crossover effect of US’s new pricing blueprint. 

Exploring new character benchmarks for today’s pharma executives, and whether they have the transformational traits to lead through change.

My first gathering of Pharm Exec's Editorial Advisory Board was both an honor and a learning experience-about us, the industry, and maintaining our mission to the our readers.

Laboratory testing has become a critical access point for sales teams in the age of personalized medicine.

From AI to Alexa, experts in specialty pharma ponder the possibilities for high tech and the patient journey.

There is no magic bullet that will dramatically impact drug pricing to everybody’s liking. But a stepwise approach involving a series of reforms, including taking advantage of the next midterm elections, could point the path toward a solution.

Pharm Exec’s 18th annual listing of the top biopharma players shows that most of the familiar placeholders are holding their ground as they weigh a changing business climate with new opportunities for growth in a potentially resurgent marketplace.

Click the title above to open the Pharmaceutical Executive June 2018 issue in an interactive PDF format.